Related Experiment Videos
Adjuvant therapy for sarcomas
1Division of Clinical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Seminars in Oncology
|December 1, 1991
Summary
Adjuvant chemotherapy shows limited survival benefits for adult soft-tissue sarcomas. Further research is needed to identify high-risk patients who may benefit from this investigational treatment.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Adjuvant chemotherapy is standard for certain pediatric sarcomas like osteosarcoma and Ewing's sarcoma.
- Its role in adult soft-tissue sarcomas remains controversial and requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of adjuvant chemotherapy in adult soft-tissue sarcomas based on existing randomized trials.
- To determine the appropriate patient populations for future adjuvant chemotherapy trials in soft-tissue sarcomas.
Main Methods:
- Systematic review and analysis of 12 randomized controlled trials of adjuvant chemotherapy for soft-tissue sarcomas.
- Examination of overall survival, disease-free survival (DFS), and subset analyses based on tumor location and grade.
Main Results:
- Only 2 of 12 trials showed a significant overall survival advantage for adjuvant chemotherapy.
- Three trials reported superior survival in the observation arm compared to chemotherapy.
- Subset analyses indicated potential DFS benefits for extremity lesions, but not overall survival, with some analyses showing worse outcomes in the chemotherapy arm.
- Doxorubicin-related cardiotoxicity occurred in approximately 10% of patients.
Conclusions:
- Adjuvant chemotherapy should be considered investigational for adult soft-tissue sarcomas.
- Future trials should focus on high-risk metastatic patients (large, high-grade lesions) with achievable local control.
- Low-grade sarcomas, with high surgical cure rates, should be excluded from adjuvant trials.